Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
Open accessThe DOI matches its Crossref record; 621 of the 628 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected women have marked insulin resistance, independent of obesity. This article summarizes the state of the science since we last reviewed the field in the Endocrine Reviews in 1997. There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity. There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary. Constitutive activation of serine kinases in the MAPK-ERK pathway may contribute to resistance to insulin's metabolic actions in skeletal muscle. Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis. Genetic disruption of insulin signaling in the brain has indicated that this pathway is important for ovulation and body weight regulation. These insights have been directly translated into a novel therapy for PCOS with insulin-sensitizing drugs. Furthermore, androgens contribute to insulin resistance in PCOS. PCOS may also have developmental origins due to androgen exposure at critical periods or to intrauterine growth restriction. PCOS is a complex genetic disease, and first-degree relatives have reproductive and metabolic phenotypes. Several PCOS genetic susceptibility loci have been mapped and replicated. Some of the same susceptibility genes contribute to disease risk in Chinese and European PCOS populations, suggesting that PCOS is an ancient trait.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance and hyperinsulinemia, either directly or indirectly, through factors such as adiposity can lead to increase circulating androgen levels (6).”
From Obstructive sleep apnea syndrome in polycystic ovary syndrome: a systematic review and meta-analysis (2025) · cites this paper as [6]
In the citing paper
“Androgen excess favors visceral fat deposition and lipid dysfunction with a vicious cycle of worsening of hyperinsulinemia and insulin resistance (6).”
From Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis (2024) · cites this paper as [6]
In the citing paper
“primarily due to hyperinsulinemia resulting from insulin resistance, which increases ovarian androgen production [162, 163].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [163]
In the citing paper
“Moreover, women who have both obesity and PCOS exhibit a greater level of insulin resistance in comparison to obese persons who do not have PCOS [53].”
In the citing paper
“Consensus is yet to be achieved in lean women with PCOS as IR is not consistently demonstrated (Diamanti-Kandarakis and Dunaif, 2012).”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Diamanti-Kandarakis and Dunaif, 2012
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Research works printed but not linked: 5
- Achard, 1921, Le virilisme et son association à l'insuffisance glycolytique (diabète des femmes à barbe), Bull Acad Natl Med (Paris), 86, 51
- Vague, 1947, La différentiation sexuelle. Facteur determinant des formes de l'obesité, Presse Med, 55, 339
- Chereau, 1844, Mémoires pour servir à l'étude des malades ovaires
- Givens, 1992, Historical Overview of the Polycystic Ovary, 3
- Zawadzki, 1992, Diagnostic criteria for polycystic ovary syndrome; towards a rational approach, 377
Cited by
Items 901–1,000 of 1,006
Chen, Y., Zhang, Q., Ma, J., & Yu, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.963213 · Cited by 18
Bisht, A., Gururani, R., Jain, S., Shukla, R., Dwivedi, J., & Sharma, S. K. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116206 · Cited by 17
Hyperandrogenism during puberty in the development of polycystic ovary syndrome
Nader, S. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.03.013 · Cited by 17
Normal weight obesity among young adults in Trinidad and Tobago: prevalence and associated factors
Ramsaran, C., & Maharaj, R. G. (2015) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2015-0042 · Cited by 17
Bodur, S., Dundar, O., Kanat-Pektas, M., Kinci, M. F., & Tutuncu, L. (2018) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2018.04.015 · Cited by 14
Adipose Tissue is a Potential Source of Hyperandrogenism in Obese Female Rats
Wagner, I. V., Sahlin, L., Savchuk, I., Klöting, N., Svechnikov, K., & Söder, O. (2018) · Obesity · doi:10.1002/oby.22198 · Cited by 17
“hyperinsulinism enhance ovarian and adrenal androgen secretion in women with obesity (11,12).”
BackgroundAmini, P., Samani, R. O., Hosseini, R., Ahmadi, J., & Maroufizadeh, S. (2018) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2018.07.005 · Cited by 17
Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome
Rosenfield, R. L., Barnes, R. B., & Ehrmann, D. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00133-5 · Cited by 17
Zhou, J., Zuo, W., Tan, Y., Wang, X., Zhu, M., & Zhang, H. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01130-4 · Cited by 16
“It also increases the risk for dyslipidemia, type 2 diabetes, obesity and cardiovascular disease [2, 3].”
BackgroundMesa, A., Franch‐Nadal, J., Navas, E., & Mauricio, D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02791-9 · Cited by 16
“This hyperinsulinemic state stimulates ovarian androgen production through its co-gonadotropic action [123], subsequently promoting visceral fat accumulation.”
Jala, A., Varghese, B., Kaur, G., Karthikraj, R., Dutta, R., Adela, R., & Borkar, R. M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-21612-0 · Cited by 16
“Abbreviations PCOS: Polycystic ovarian syndrome; EDCs: Endocrine-disrupting chemicals; PCOM: Polycystic ovarian morphology; NIH: National Institute of Health; PCBs: Polychlorinated biphenyls; PFAS: Per- and poly-fluoroalkyl substances; LC–MS/MS: Liquid chromatography tandem mass spectrometry; GC-MS: Gas chromatography…”
BackgroundInfluentialOllila, M., Hoek, A., & Piltonen, T. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad083 · Cited by 16
Geng, Y., Liu, Z., Hu, R., Ma, W., Wu, X., Dong, H., Song, K., Xu, X., Huang, Y., Li, F., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01236-9 · Cited by 16
“Androgen, for one thing, can modify the secretion of adipokines and promote visceral fat accumulation hence inhibiting insulin sensitivity in adipose tissue and skeletal muscles [75].”
BackgroundGao, J., Song, X., Ou, H., Cheng, X., Zhang, L.-S., Liu, C., Dong, Y., & Wang, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1388074 · Cited by 16
Effects of mind-body interventions on polycystic ovary syndrome: a comprehensive meta-analysis
Zhao, K., Nie, L., Ye, X., & Hu, X. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01477-2 · Cited by 18
“Extensive research has consistently demonstrated that regardless of the specific PCOS subtype, there exists a close association with insulin resistance, type 2 diabetes, and cardiovascular diseases [3, 49].”
BackgroundWeng, L., Zhu, Q., Xiang, Y., Cao, T., Cai, J., Liang, N., Hong, X., Xue, M., & Ge, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113327 · Cited by 16
PCOS and the Genome: Is the Genetic Puzzle Still Worth Solving?
Palumbo, M., Corte, L. D., Colacurci, D., Ascione, M., D’Angelo, G., Baldini, G. M., Giampaolino, P., & Bifulco, G. (2025) · Biomedicines · doi:10.3390/biomedicines13081912 · Cited by 16
“Such features are strongly associated with worsened endocrine and metabolic profiles, reinforcing the hypothesis of a metabolic phenotype of PCOS [3,4].”
Ribeiro, M. P., Lemos, C., Leal, C., Barreiro, M., Tomé, A., & Vale-Fernandes, E. (2025) · JBRA · doi:10.5935/1518-0557.20250040 · Cited by 17
“…to various metabolic disorders, including infertility, obesity, diabetes mellitus, and an increased risk of long-term pregnancy complications and cardiovascular diseases (Solomon et al ., 2002; Moran et al ., 2010; Wild et al ., 2011; Diamanti-Kandarakis & Dunaif, 2012; Christ et al ., 2019).”
Tepavčević, S., Milutinović, D. V., Μacut, D., Žakula, Z., Nikolič, M., Antić, I. B., Romić, S., Bjekić-Macut, J., Matić, G. M., & Korićanac, G. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.01.006 · Cited by 16
Korsoff, P., Bogl, L. H., Korhonen, P. E., Kangas, A. J., Soininen, P., Ala‐Korpela, M., Rose, R. J., Kaaja, R., & Kaprio, J. A. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00028 · Cited by 16
“In addition to these important reproductive outcomes, hyperandrogenism is associated with an adverse metabolic profile, including obesity, particularly abdominal obesity (4), hypertension (5), insulin resistance (6), type 2 diabetes (7), dyslipidemia (8, 9), and subclinical atherosclerosis leading to increased cardiov…”
BackgroundSerum irisin concentrations in lean adolescents with polycystic ovary syndrome
Bacopoulou, F., Athanasopoulos, N., Efthymiou, V., Mantzou, A., Aravantinos, L., Vlahopoulos, S., & Deligeoroglou, E. (2018) · Clinical Endocrinology · doi:10.1111/cen.13555 · Cited by 16
Lu, C. Y., Hutchens, E. G., Farhy, L. S., Bonner, H., Suratt, P. M., & McCartney, C. R. (2018) · Neuroendocrinology · doi:10.1159/000488110 · Cited by 16
Chehin, M. B., Fraietta, R., Lorenzon, A. R., Bonetti, T. C., & Motta, E. L. A. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120906866 · Cited by 16
The emerging role of the gut microbiome in polycystic ovary syndrome
He, Y., Jin, X., Wang, H., Dai, H., Lu, X., Zhao, J., Zhang, H., Chen, W., & Wang, G. (2021) · F&S Reviews · doi:10.1016/j.xfnr.2021.03.003 · Cited by 16
Bioinformatics analysis of the molecular mechanism of obesity in polycystic ovary syndrome
Zhou, J., Huang, X., Xue, B., Wei, Y., & Hua, F. (2021) · Aging · doi:10.18632/aging.202938 · Cited by 17
“The insulin resistance in PCOS is usually resulted from abnormal insulin signalling, metabolic dysfunction in insulinresponsive tissues, and importantly, the increased volume of fat tissues [4, 5].”
BackgroundKe, Y., Hu, J., Zhu, Y., Wang, Y., Chen, S., & Liu, S. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-00841-1 · Cited by 16
“In general, the role of insulin in cells is mainly through activation of phosphatidylinositol 3 kinase (PI3K) and mitogen-activated protein kinase (MAPK) [24, 25].”
BackgroundRasool, S. U. A., Nabi, M., Ashraf, S., & Amin, S. (2022) · Genes · doi:10.3390/genes13081463 · Cited by 16
“Insulin receptor substrate-1 (IRS-1) is a critical element in insulin signaling pathways, and mutations in theIRS-1gene have been reported to have a role in determining susceptibility to traits such as impaired sensitivity to insulin-related to type 2 diabetes [15,27].”
BackgroundWomen With Polycystic Ovary Syndrome: A Review of Susceptibility to Type 2 Diabetes
Layacha, S. Y., & Biswas, D. A. (2023) · Cureus · doi:10.7759/cureus.33390 · Cited by 16
“The signalling flaw specifically affected the insulin metabolic pathway and resulted in reduced protein kinase phosphorylation [27].”
BackgroundPolycystic Ovary Syndrome in Adolescents
Saleh, F., Starkman, H., Furness, A., Pfeifer, S. M., & Kives, S. L. (2024) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2024.08.005 · Cited by 16
Diané, A., Kupreeva, M., Borthwick, F., Proctor, S. D., Pierce, W. D., & Vine, D. F. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0711 · Cited by 16
Figurová, J., Dravecká, I., Petríková, J., Javorský, M., & Lazúrová, I. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0039 · Cited by 16
Petraitienė, I., Valūnienė, M., Jarienė, K., Šeibokaitė, A., Albertsson-Wikland, K. G., & Verkauskienė, R. (2019) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2019.11.001 · Cited by 16
Fruzzetti, F., Benelli, E., Fidecicchi, T., & Tonacchera, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/2901393 · Cited by 16
“When IR is present, high insulin levels impair the normal secretion of LH and FSH from pituitary cells and their function in the ovaries, promoting premature luteinization of follicles [4, 44] Although their effects on gonadotropins and on inflammation, the ability of ALA and MI to restore normal levels of insulin in…”
BackgroundLivadas, S., Μacut, D., Bothou, C., Kuliczkowska-Płaksej, J., Vryonidou, A., Bjekić-Macut, J., Mouslech, Z., Milewicz, A., & Panidis, D. (2020) · HORMONES · doi:10.1007/s42000-020-00211-z · Cited by 16
González, F., Mather, K. J., Considine, R. V., Abdelhadi, O. A., & Acton, A. J. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00228.2020 · Cited by 16
Butler, A. E., Abouseif, A., Dargham, S. R., Sathyapalan, T., & Atkin, S. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-75109-2 · Cited by 16
Siemienowicz, K. J., Rae, M. T., Howells, F., Anderson, C., Nicol, L. M., Franks, S., & Duncan, W. C. (2020) · iScience · doi:10.1016/j.isci.2020.101164 · Cited by 16
Hayes, M. G., Urbanek, M., Ehrmann, D. A., Armstrong, L. L., Lee, J. Y., Sisk, R. K., Karaderi, T., Barber, T. M., McCarthy, M. I., Franks, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms10762 · Cited by 16
Self-citationObstructive sleep apnea syndrome in polycystic ovary syndrome: a systematic review and meta-analysis
Abdul Jafar, N. K., Al Balushi, A., Subramanian, A., Lee, S. I., Bennett, C. J., Moran, L. J., Mousa, A., Tay, C. T., Teede, H. J., & Mansfield, D. R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532519 · Cited by 15
Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome
Barber, T. M., & Franks, S. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2013.827373 · Cited by 15
Kulshreshtha, B., Sharma, N., Pant, S., Sharma, L., Pahuja, B., & Singh, P. (2022) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.12.023 · Cited by 15
Different sleep pattern in over-weight/obese women with polycystic ovary syndrome
Öberg, E., Blomberg, L., Åkerstedt, T., & Hirschberg, A. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1068045 · Cited by 15
Misra, S., Gada, J. V., Dhole, C., Varthakavi, P. K., & Bhagwat, N. M. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01374-x · Cited by 15
“However, several investigators have only shown early beta-cell malfunction and delayed (2nd phase) hyperinsulinemia [20, 29].”
Female-specific risk factors for cardiovascular disease: an update
Theodorou, A., Karagiannakis, D. S., Stefanaki, K., Kassi, E., Peppa, Μ., Vryonidou, A., & Paschou, S. Α. (2024) · HORMONES · doi:10.1007/s42000-024-00576-5 · Cited by 16
“It has been suggested that PCOS may have its origins in utero [41, 46].”
InfluentialSankaranarayanan, L., Brewer, K., Morrow, S., Johnson, G. D., Barrera, A., Venukuttan, R., Sisk, R. K., Dunaif, A. E., & Reddy, T. E. (2025) · Nature Communications · doi:10.1038/s41467-025-62884-7 · Cited by 16
“In the forskolin treated cells, we observed a 4-fold increase in DENND1A expression when targeting dCas9-P300 to the DENND1A promoter, and a 1.8 fold to 2-fold increase in DENND1A expression while targeting regulatory elements 2,3 and 4.”
InfluentialSelf-citationPalomaki, G. E., Kalra, B., Kumar, T., Patel, A., Savjani, G. V., Torchen, L. C., Dunaif, A. E., Morrison, A., Lambert-Messerlian, G. M., & Kumar, A. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.12.012 · Cited by 15
“menses per year, with exclusion of other hyperandrogenic disorders of the ovaries, adrenals, and pituitary (4).”
BackgroundMethodSelf-citationVilariño‐García, T., Guadix, P., Dorado-Silva, M., Sánchez-Martín, P., Pérez‐Pérez, A., & Sánchez‐Margalet, V. (2022) · Cells · doi:10.3390/cells11182821 · Cited by 15
“It has been reported that PCOS is a highly hereditary condition, with an approximately 70% concordance in monozygotic twins, which suggests a genetic contribution to its pathogenesis [4].”
BackgroundA bibliometric and visual analysis of obesity and polycystic ovary syndrome from 2012 to 2022
Luo, P., Li, J., Li, P., Wang, G., Li, W., Song, Z. J., Sun, X., Fu, Z., Zhou, H., Yi, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1011105 · Cited by 15
“in 2012 (23) and reported an update on mechanisms and implications of IR and PCOS with 874 citations, which was higher than that of the second paper (525 citations) (24).”
BackgroundHan, Y., Lin, B., Lu, W., Wang, X., Tang, W., Tao, X., Cai, H., He, C., & Liu, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1057376 · Cited by 11
Early pregnancy complications including recurrent pregnancy loss and obesity
Potdar, N., & Iyasere, C. (2023) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2023.102372 · Cited by 15
Hepatokine Profile in Adolescents with Polycystic Ovary Syndrome: A Case–Control Study
Giannouli, A., Stefanaki, C., Kouskoutis, C., Konidari, M., Mani, I., Konidari, K., Markantonis, S. L., Mantzou, A., Dourakis, S. P., Deligeoroglou, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175744 · Cited by 15
Hepatokines: the missing link in the development of insulin resistance and hyperandrogenism in PCOS?
Stefanaki, K., Ilias, Ι., Paschou, S. Α., & Karagiannakis, D. S. (2023) · HORMONES · doi:10.1007/s42000-023-00487-x · Cited by 15
“Insulin acts as co-gonadotropin by enhancing CYP17α activity, which results in hyperandrogenism; it is also an important regulator of SHBG production [25].”
BackgroundMacruz, C. F., Lima, S. M. R. R., Salles, J. E. N., da Silva, G. M. D., & Scalissi, N. M. (2017) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12066 · Cited by 15
“β-cell dysfunction affects patients with PCOS who are obese and those who are not, although this is not associated with glucose intolerance in the majority of women [15].”
BackgroundBicer, M., Alan, M., Alarslan, P., Guler, A., Kocabaş, G. Ü., İmamoğlu, Ç., Akşit, M., Bozkaya, G., Isil, A. M., Baloğlu, A., et al. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0917-x · Cited by 15
Guo, Z., Chen, X., Feng, P., & Yu, Q. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00813-0 · Cited by 15
“rapamycin on the ovaries, steroidogenesis can also be indirectly altered by changes in insulin resistance and metabolic actions induced by rapamycin, which can further exacerbate ovulatory disturbances [25].”
BackgroundSangouni, A. A., Sasanfar, B., Ghadiri‐Anari, A., & Hosseinzadeh, M. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.08.005 · Cited by 15
Curcumin and Polycystic Ovary Syndrome: a Systematic Review
Shojaei‐Zarghani, S., Molani‐Gol, R., & Rafraf, M. (2022) · Reproductive Sciences · doi:10.1007/s43032-021-00826-6 · Cited by 16
Polycystic ovary syndrome is associated with increased osteopontin levels
Saklamaz, A., Çalan, M., Yilmaz, O., Küme, T., Temür, M., Yildiz, N., Kasap, E., Genç, M., Yürekli, B. Ş., & Kocabaş, G. Ü. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1074 · Cited by 15
Serum homocysteine is associated with polycystic ovarian syndrome in Jordan
Saadeh, N. A., Alfaqih, M. A., Mansour, H., Khader, Y. S., Saadeh, R., Al‐Dwairi, A., & Nusier, M. K. (2018) · Biomedical Reports · doi:10.3892/br.2018.1149 · Cited by 15
“Furthermore, IR in these women appears to contribute to PCOS development (4).”
Polycystic Ovary Syndrome and Obesity
Barber, T. M., Dimitriadis, G. K., & Franks, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-19821-7_15 · Cited by 15
Guo, Y., Liu, Y., Yan, X., Ding, R., Tan, H., & Wang, L. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056478 · Cited by 14
Polycystic Ovary Syndrome: pathogenesis, management, and treatment with metals and organic compounds
Al-Kareem, T. A. A., Hassan, S., & Abdalhadi, S. M. (2024) · Cellular Molecular and Biomedical Reports · doi:10.55705/cmbr.2023.406103.1160 · Cited by 14
Wang, A., Noel, M., Christ, J. P., Corley, J., Lenhart, N. J., Cedars, M. I., & Huddleston, H. G. (2023) · F&S Reports · doi:10.1016/j.xfre.2023.12.004 · Cited by 15
“Although not required for diagnosis, individuals with PCOS also show increased rates of insulin resistance and other associated metabolic comorbidities (3).”
BackgroundPorth, R., Oelerich, K., & Sivanandy, M. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041056 · Cited by 17
Dube, R., Bambani, T., Saif, S., Hashmi, N., Patni, M. A., & Kedia, N. R. (2024) · Diabetology · doi:10.3390/diabetology5040032 · Cited by 14
“It has also been reported that IR is present in PCOS even with normal BMI [79].”
Przewocki, J., Łukaszuk, A., Jakiel, G., Wocławek-Potocka, I., Kłosińska, K., Olszewska, J., & Łukaszuk, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111749 · Cited by 14
“PCOS is a multifaced endocrine disorder characterised by hyperandrogenism, insulin resistance, and chronic anovulation, all of which contribute to a disrupted ovarian microenvironment [6].”
BackgroundAssociation between cardiometabolic index and female infertility: A population-based study
Kong, L., Xian, D., Wang, Q., Xie, R., Sun, F., Zhou, N., Li, C., Chen, X., & Qian, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0313576 · Cited by 14
On the Intimate Relationship of Adiposity to Polycystic Ovary Syndrome
Rosenfield, R. L., & Dumesic, D. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf527 · Cited by 15
Adamska, A., Łebkowska, A., Jacewicz‐Święcka, M., Krentowska, A., Hryniewicka, J., Wołczyński, S., Górska, M., & Kowalska, I. (2017) · International Journal of Endocrinology · doi:10.1155/2017/2316986 · Cited by 14
“Polycystic ovary syndrome (PCOS) is a frequent endocrinopathy which affects about 5–10% of reproductive-aged women [1].”
BackgroundLi, D., Bai, P., Wu, J.-Y., Xie, M., Zhao, R., Wang, Z.-P., & Qi, X. (2021) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-021-3290-0 · Cited by 14
“Moreover, some patients are usually non-tolerant to these treatments and prone to recurrence, and the longterm therapeutic effects and safety are unclear.((6,7))”
BackgroundKumawat, M., Choudhary, P., & Aggarwal, S. (2021) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_35_21 · Cited by 14
ANGPTL4 Expression in Ovarian Granulosa Cells Is Associated With Polycystic Ovary Syndrome
Jiang, Q., Pan, Y., Li, P., Zheng, Y., Bian, Y., Wang, W., Wu, G., Song, T., & Shi, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.799833 · Cited by 14
The Roles of Autophagy in the Genesis and Development of Polycystic Ovary Syndrome
Cheng, D., Zheng, B., Sheng, Y., Zeng, Z., & Mo, Z. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01255-3 · Cited by 14
“PCOS is the most common cause of infertility in women, characterized by HA, OA, IR, and obesity [106].”
BackgroundJi, R., Zhang, Z., Yang, Z., Chen, X., Yin, T., & Yang, J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05091-1 · Cited by 14
“The clinical manifestations of PCOS include hyperandrogenism and oligoovulation, which are generally accompanied by metabolic abnormalities such as insulin resistance (IR), obesity, and cardiovascular diseases [2–4].”
BackgroundDutkiewicz, E., Rachoń, D., Dziedziak, M., Kowalewska, A., & Moryś, J. M. (2024) · Archives of Women s Mental Health · doi:10.1007/s00737-024-01500-x · Cited by 14
“Polycystic Ovary Syndrome (PCOS) is a heterogenous endocrine disorder characterized by hyperandrogenism of ovarian origin and intrinsic insulin resistance (IR) (Azziz et al. 2016; Diamanti-Kandarakis & Dunaif 2012).”
Female Genomics: Infertility and Overall Health
Joshi, N., & Chan, J. L. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603095 · Cited by 14
Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients
Stracquadanio, M., Ciotta, L., & Palumbo, M. A. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1418852 · Cited by 14
“Insulin resistance (IR) and the associated metabolic abnormalities (visceral obesity and hypertension) are frequent findings in women with PCOS [5].”
BackgroundSolorzano, C. M. B., Knudsen, K. L., Anderson, A. D., Hutchens, E. G., Collins, J. S. P., Patrie, J. T., Marshall, J. C., & McCartney, C. R. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00131 · Cited by 14
“Insulin resistance has long been associated with hyperandrogenemia (3, 4).”
BackgroundYang, Y., Ding, M., Di, N., Azziz, R., Yang, D., & Zhao, X. (2018) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22699 · Cited by 14
Hyperandrogenemia is Common in Asymptomatic Women and is Associated with Increased Metabolic Risk
Torchen, L. C., Tsai, J. N., Jasti, P., Macaya, R., Sisk, R. K., Dapas, M., Hayes, M. G., Urbanek, M., & Dunaif, A. E. (2019) · Obesity · doi:10.1002/oby.22659 · Cited by 15
“In addition, HA-EM women had lower I0 and postchallenge insulin levels compared with women with PCOS (4), suggesting that they were more insulin sensitive.”
BackgroundInfluentialSelf-citationLanders, R. S. M., Padmanabhan, V., & Cardoso, R. C. (2020) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00667-z · Cited by 14
“bolic disturbances, such as obesity and insulin resistance [4].”
BackgroundFetal programming by androgen excess impairs liver lipid content and PPARg expression in adult rats
Silva, A. F., Abruzzese, G. A., Ferrer, M. J., Heber, M. F., Ferreira, S. R., Cerrone, G. E., & Motta, A. B. (2021) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174421000416 · Cited by 15
Hara, S., Takahashi, T., Amita, M., Matsuo, K., Igarashi, H., & Kurachi, H. (2013) · Journal of Ovarian Research · doi:10.1186/1757-2215-6-69 · Cited by 14
“Insulin resistance with compensatory hyperinsulinemia is observed in approximately 70% of patients with PCOS, irrespective of obesity [12,13].”
Thomas, J. L., Rajapaksha, M., Mack, V. L., DeMars, G., Majzoub, J. A., & Bose, H. S. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219550 · Cited by 14
“Premature adrenarche may represent a forerunner condition for polycystic ovarian syndrome, insulin resistance, or metabolic syndrome (Ibanez et al., 2009; Diamanti-Kandarakis and Dunaif, 2012).”
BackgroundGourgari, E., Spanakis, E. K., & Dobs, A. S. (2016) · International Journal of Women s Health · doi:10.2147/ijwh.s104825 · Cited by 14
“20 These studies indicate that older age is a risk factor for IR.”
BackgroundInfluentialDuan, J., Cai, H., Huang, Y., & Shi, L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.689916 · Cited by 13
Escobar-Morreale, H. F., Martínez-García, M. Á., Insenser, M. R., Cañellas, N., Correig, X., & Luque‐Ramírez, M. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00547-2 · Cited by 13
“…a vicious circle from early ages, whereby hyperandrogenism may contribute to insulin resistance and hyperinsulinism by favoring visceral adiposity, and these metabolic derangements, in turn, may promote further ovarian androgen excess [5], because insulin acts as a co-gonadotropin at the ovary [6].”
BackgroundRuane, P. T., Paterson, I., Reeves, B., Adlam, D. J., Berneau, S., Renshall, L., Brosens, J. J., Kimber, S. J., Brison, D. R., Aplin, J., et al. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00559.2023 · Cited by 13
Kelly, F. A., Lôbo, A. D. O. M., Cardoso, J. H. C. O., & de Moraes, F. C. A. (2024) · Endocrine · doi:10.1007/s12020-024-04052-3 · Cited by 13
“This disease is commonly associated with metabolic disorders, such as insulin resistance, which also play a role in increasing the LH pulsatile frequency secretion and, consequently, the androgen synthesis, characterizing a self-perpetuating cycle of the disease [27 – 30].”
Polyendocrine metabolic ovarian syndrome in pregnancy: pathophysiology and outcomes
Teede, H. J., Vanky, E., Piltonen, T., Stener‐Victorin, E., Moran, L., & Khomami, M. B. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01261-w · Cited by 13
“An altered adipokine profile, such as reduced adiponectin, further impairs metabolic homeostasis 67,70–72 .”
Underdal, M. O., Salvesen, Ø. O., Henriksen, A. H., Andersen, M., & Vanky, E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz053 · Cited by 14
Hasegawa, R., Iwase, I., Takagi, T., Kondo, M., Matsui, M., & KAWASHIMA, C. (2019) · Animal Science Journal · doi:10.1111/asj.13300 · Cited by 13
Impact of interlukin-6 on central obesity measures in women with polycystic ovarian syndrome
Alissa, E. M., Algarni, S. A., Khaffji, A. J., & Mansouri, N. M. A. (2020) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1697219 · Cited by 13
Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS?
Livadas, S., Bothou, C., Kuliczkowska-Płaksej, J., Robeva, R., Vryonidou, A., Macut, J. B., Androulakis, I., Opalic, M., Mouslech, Z., Milewicz, A., et al. (2022) · Endocrine Connections · doi:10.1530/ec-21-0358 · Cited by 13
Genazzani, A. D., Battipaglia, C., Semprini, E., Arnesano, M., Ambrosetti, F., Sponzilli, A., Tomatis, V., & Petrillo, T. (2022) · Endocrines · doi:10.3390/endocrines3020024 · Cited by 13
Meshkani, M., Saedisomeolia, A., Yekaninejad, M. S., Mousavi, S. A., Ildarabadi, A., & Dastjerdi, M. V. (2022) · Clinical Nutrition Research · doi:10.7762/cnr.2022.11.4.241 · Cited by 13
“Most studies have focused on the development of abdominal obesity, insulin resistance and hyper-insulinemia, glucose intolerance, increased risk of type 2 diabetes mellitus (DM2), dyslipidemia (hyper-triglycridemia and low high-density lipoprotein (HDL) cholesterol) and hypertension which can elevate the risk of ather…”
BackgroundLi, Y., Jiang, Y., Zhang, S., Liu, H., & Zhang, C. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s399105 · Cited by 13
“Direct, dynamic methods for measuring IR are accurate but inconvenient for clinical practice in large populations.(14) Currently, HOMA-IR is suggested to be associated with IVF/ICSI outcomes in infertile patients undergoing IVF/ICSI cycles.”
MethodMetformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review
Alfaraidi, H., & Samaan, M. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1072879 · Cited by 13
Danowska, M., & Strączkowski, M. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2174-7958 · Cited by 13
Beyond counting sheep: Exploring the link between polycystic ovary syndrome and sleep health
Jafar, N. K. A., Bennett, C. J., Moran, L. J., & Mansfield, D. R. (2023) · Seminars in Reproductive Medicine · doi:10.1055/s-0043-1777724 · Cited by 12
“16 Excess adipose tissue further worsens the presentation of PCOS likely through the contribution of extrinsic IR associated with weight gain.”
Background
Metadata
- Authors
- Diamanti-Kandarakis, E., & Dunaif, A.
- Affiliations
- Medical School, University of Athens (E.D.-K.), Athens GR-14578, Greece
- Northwestern University (US)
- ORCID
- Dunaif, Andrea
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2012-10-12
- Volume
- 33
- Issue
- 6
- Pages
- 981-1030
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC5393155
- OpenAlex
- W1967263394
- Semantic Scholar
- b2b7fa060bf61f261edf17bef51cbbbd222742e0
- Cited by
- 1,947
- References
- 628
- Citations by year
- 2026: 183 · 2025: 178 · 2024: 182 · 2023: 221 · 2022: 191 · 2021: 184 · 2020: 136 · 2019: 140 · 2018: 108 · 2017: 97 · 2016: 96 · 2015: 92 · 2014: 91 · 2013: 43 · 2012: 4
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073411)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD044405, R01HD057223, U54HD034449)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, insulin resistance, insulin receptor signaling, MAPK/ERK pathway, skeletal muscle insulin sensitivity, ovarian steroidogenesis, ovulation, brain insulin signaling, body weight regulation, insulin-sensitizing drugs, androgens, developmental origins of health and disease, fetal growth restriction, genetic susceptibility loci, type 2 diabetes risk, lean PCOS
- MeSH terms
- Female, Humans, Insulin Resistance, Phenotype, Polycystic Ovary Syndrome, Reproduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.